CA2851018C - Lactic acid bacteria having action of lowering blood uric acid level - Google Patents
Lactic acid bacteria having action of lowering blood uric acid level Download PDFInfo
- Publication number
- CA2851018C CA2851018C CA2851018A CA2851018A CA2851018C CA 2851018 C CA2851018 C CA 2851018C CA 2851018 A CA2851018 A CA 2851018A CA 2851018 A CA2851018 A CA 2851018A CA 2851018 C CA2851018 C CA 2851018C
- Authority
- CA
- Canada
- Prior art keywords
- lactic acid
- acid bacteria
- purine
- lactobacillus
- acid bacterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 284
- 239000004310 lactic acid Substances 0.000 title claims abstract description 142
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 142
- 241000894006 Bacteria Species 0.000 title claims abstract description 135
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title abstract description 51
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title abstract description 49
- 229940116269 uric acid Drugs 0.000 title abstract description 49
- 210000004369 blood Anatomy 0.000 title description 29
- 239000008280 blood Substances 0.000 title description 29
- 230000009471 action Effects 0.000 title description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims abstract description 54
- 241000186784 Lactobacillus oris Species 0.000 claims abstract description 37
- 235000005911 diet Nutrition 0.000 claims description 47
- 230000000378 dietary effect Effects 0.000 claims description 41
- 201000001431 Hyperuricemia Diseases 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 38
- 239000000047 product Substances 0.000 claims description 37
- 238000004519 manufacturing process Methods 0.000 claims description 23
- 239000000126 substance Substances 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 208000024891 symptom Diseases 0.000 claims description 16
- 201000005569 Gout Diseases 0.000 claims description 14
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 9
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 230000008085 renal dysfunction Effects 0.000 claims description 9
- 208000009911 Urinary Calculi Diseases 0.000 claims description 7
- 239000013067 intermediate product Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 abstract description 28
- 241000186606 Lactobacillus gasseri Species 0.000 abstract description 22
- 241000700159 Rattus Species 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 12
- 239000007857 degradation product Substances 0.000 abstract description 4
- 241000186660 Lactobacillus Species 0.000 description 35
- 230000001580 bacterial effect Effects 0.000 description 35
- 229940039696 lactobacillus Drugs 0.000 description 31
- 235000013305 food Nutrition 0.000 description 21
- 239000000463 material Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 17
- 235000013618 yogurt Nutrition 0.000 description 17
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 14
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 150000003212 purines Chemical class 0.000 description 13
- 239000007858 starting material Substances 0.000 description 13
- 239000007789 gas Substances 0.000 description 12
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 239000006285 cell suspension Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 244000005700 microbiome Species 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 7
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 7
- 241000194020 Streptococcus thermophilus Species 0.000 description 7
- 235000013365 dairy product Nutrition 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 229940029575 guanosine Drugs 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 6
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 6
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 6
- 229930010555 Inosine Natural products 0.000 description 6
- 240000001929 Lactobacillus brevis Species 0.000 description 6
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 6
- 241000186840 Lactobacillus fermentum Species 0.000 description 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 235000015140 cultured milk Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 229960003786 inosine Drugs 0.000 description 6
- 229950000193 oteracil Drugs 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000010171 animal model Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 4
- 230000000384 rearing effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 206010052804 Drug tolerance Diseases 0.000 description 3
- 238000012404 In vitro experiment Methods 0.000 description 3
- 235000013351 cheese Nutrition 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000026781 habituation Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 229940012969 lactobacillus fermentum Drugs 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- 102000004008 5'-Nucleotidase Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 206010007027 Calculus urinary Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007836 KH2PO4 Substances 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- 102100033220 Xanthine oxidase Human genes 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- 229950006790 adenosine phosphate Drugs 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 2
- 235000013928 guanylic acid Nutrition 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 208000008281 urolithiasis Diseases 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- KHWCHTKSEGGWEX-RRKCRQDMSA-N 2'-deoxyadenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 KHWCHTKSEGGWEX-RRKCRQDMSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- LTFMZDNNPPEQNG-KVQBGUIXSA-N 2'-deoxyguanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 LTFMZDNNPPEQNG-KVQBGUIXSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 108010012029 Guanine Deaminase Proteins 0.000 description 1
- 102000013587 Guanine deaminase Human genes 0.000 description 1
- 241000186713 Lactobacillus amylovorus Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 241000218492 Lactobacillus crispatus Species 0.000 description 1
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 1
- 241000509544 Lactobacillus gallinarum Species 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 244000132194 Lactobacillus helveticus subsp jugurti Species 0.000 description 1
- 235000005448 Lactobacillus helveticus subsp jugurti Nutrition 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 241000218587 Lactobacillus paracasei subsp. paracasei Species 0.000 description 1
- 241000186684 Lactobacillus pentosus Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000001790 Welch's t-test Methods 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000009603 aerobic growth Effects 0.000 description 1
- GZCGUPFRVQAUEE-KVTDHHQDSA-N aldehydo-D-mannose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-KVTDHHQDSA-N 0.000 description 1
- PYMYPHUHKUWMLA-VPENINKCSA-N aldehydo-D-xylose Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-VPENINKCSA-N 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- HMFHBZSHGGEWLO-AIHAYLRMSA-N alpha-D-ribose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-AIHAYLRMSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 235000020827 calorie restriction Nutrition 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- KHWCHTKSEGGWEX-UHFFFAOYSA-N deoxyadenylic acid Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(O)=O)O1 KHWCHTKSEGGWEX-UHFFFAOYSA-N 0.000 description 1
- LTFMZDNNPPEQNG-UHFFFAOYSA-N deoxyguanylic acid Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1CC(O)C(COP(O)(O)=O)O1 LTFMZDNNPPEQNG-UHFFFAOYSA-N 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000004226 guanylic acid Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000020925 non fasting Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229940093956 potassium carbonate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 230000006825 purine synthesis Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/145—Gasseri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/163—Oris
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were measured, and several lactic acid bacteria showing remarkable purine- decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine- decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, Lactobacillus gasseri OLL2959 and Lactobacillus oris OLL2779, were found.
Description
DESCRIPTION
LACTIC ACID BACTERIA HAVING ACTION OF LOWERING BLOOD URIC ACID
LEVEL
Technical Field The present invention relates to lactic acid bacteria that have an effect of lowering the blood uric acid level and methods for using them, and also relates to foods or pharmaceuticals that comprise lactic acid bacteria for preventing and/or treating hyperuricemia.
Background Art Hyperuricemia is a condition of reduced uric acid excretion or excessive uric acid production due to environmental (lifestyle) or genetic factors, and leads to excess uric acid in the blood. Although hyperuricemia may lack subjective symptoms, it causes serious complications such as gout, renal dysfunction, urolithiasis, and arteriosclerosis. Acute arthritis with severe pain appears as a major symptom in gout, a representative complication of hyperuricemia.
Gout was once called "the regal disease" and had been a "luxury disease" of those in the ranks that frequently consumed a lot of meat, fish, alcohol, and such; however, recently, it has been increasing yearly due to changes in the diet. The current population of gout patients in Japan is 300,000 to 400,000 people, and the population of hyperuricemia patients is estimated to be 6,000,000; thus, prevention and treatment of hyperuricemia is drawing increasing attention.
Prevention and treatment of hyperuricemia is carried out by controlling the uric acid level in blood through diet therapy, exercise therapy, pharmaceuticals, and combinations thereof.
In particular, limiting caloric intake is one of the most frequently selected methods for preventing and treating hyperuricemia, but maintaining strict calorie restriction is not always easy. As a method for improving such circumstances, methods for lowering the serum uric acid level by orally ingesting microorganisms such as lactic acid bacteria and yeast that decompose purines (for example as pharmaceuticals or dietary products), and decomposing purines ingested from meals in the intestine to decrease their absorption into the body have been suggested (Patent Document 1 and Non-patent Document 1). Lactic acid bacteria have been traditionally used as foods and pharmaceuticals, and since they are highly safe to the human body, consumption of lactic acid bacteria can be an effective method for preventing,/treating hyperuricemia with little concern for side effects. Furthermore, as described above, the first choice of methods for preventing and treating hyperuricemia is diet therapy, and by ingesting lactic acid bacteria that allow control of uric acid levels as food, it may become a novel and very realistic, effective method for preventing and/or treating hyperuricemia.
Although the lactic
LACTIC ACID BACTERIA HAVING ACTION OF LOWERING BLOOD URIC ACID
LEVEL
Technical Field The present invention relates to lactic acid bacteria that have an effect of lowering the blood uric acid level and methods for using them, and also relates to foods or pharmaceuticals that comprise lactic acid bacteria for preventing and/or treating hyperuricemia.
Background Art Hyperuricemia is a condition of reduced uric acid excretion or excessive uric acid production due to environmental (lifestyle) or genetic factors, and leads to excess uric acid in the blood. Although hyperuricemia may lack subjective symptoms, it causes serious complications such as gout, renal dysfunction, urolithiasis, and arteriosclerosis. Acute arthritis with severe pain appears as a major symptom in gout, a representative complication of hyperuricemia.
Gout was once called "the regal disease" and had been a "luxury disease" of those in the ranks that frequently consumed a lot of meat, fish, alcohol, and such; however, recently, it has been increasing yearly due to changes in the diet. The current population of gout patients in Japan is 300,000 to 400,000 people, and the population of hyperuricemia patients is estimated to be 6,000,000; thus, prevention and treatment of hyperuricemia is drawing increasing attention.
Prevention and treatment of hyperuricemia is carried out by controlling the uric acid level in blood through diet therapy, exercise therapy, pharmaceuticals, and combinations thereof.
In particular, limiting caloric intake is one of the most frequently selected methods for preventing and treating hyperuricemia, but maintaining strict calorie restriction is not always easy. As a method for improving such circumstances, methods for lowering the serum uric acid level by orally ingesting microorganisms such as lactic acid bacteria and yeast that decompose purines (for example as pharmaceuticals or dietary products), and decomposing purines ingested from meals in the intestine to decrease their absorption into the body have been suggested (Patent Document 1 and Non-patent Document 1). Lactic acid bacteria have been traditionally used as foods and pharmaceuticals, and since they are highly safe to the human body, consumption of lactic acid bacteria can be an effective method for preventing,/treating hyperuricemia with little concern for side effects. Furthermore, as described above, the first choice of methods for preventing and treating hyperuricemia is diet therapy, and by ingesting lactic acid bacteria that allow control of uric acid levels as food, it may become a novel and very realistic, effective method for preventing and/or treating hyperuricemia.
Although the lactic
2 acid bacteria reported in the above-mentioned documents, Lactobacillus fermentum and Lactobacillus pentosus, are capable of decomposing purines, they have gas-producing ability and are not necessarily suitable bacterial species in terms of application as dietary products and pharmaceuticals.
[Patent Document 111 WO 2004/112809 [Non-patent Document 1] Homepage of the Japan Society for Bioscience, Biotechnology, and Agrochemistry (JSBBA), Annual Meeting of JSBBA Lecture and Presentation Database (http://jsbba.bioweb.ne.jp/jsbba_db/index.html) "JSBBA 2004.03.30 general lecture, Ikenaga, T., Kumemura, M. et al.: Effects of lactic acid bacteria on the blood uric acid levels of dietary hyperuricemia model rats"
Disclosure of the Invention The present invention may provide lactic acid bacteria that are capable of preventing and/or treating hyperuricemia, which are suitable for use in dietary products or pharmaceuticals, and at the same time to provide compositions that use the above-mentioned lactic acid bacteria for preventing and/or treating hyperuricemia.
The present inventors persistently made dedicated efforts to arrive at the present invention. First, various lactic acid bacteria were cultured in the presence of inosine and guanosine, and the amount of the above-mentioned nucleosides consumed and the amount of degradation products (hypoxanthine and guanine) produced were determined.
Then, several lactic acid bacteria with remarkable nucleoside-decomposing ability were selected. Lactic acid bacteria assessed to have high nucleoside-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and the serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on the serum uric acid level was examined. As a result, lactic acid bacteria which significantly suppress the increase of serum uric acid level were found:
Lactobacillus oris 0LL2779 and Lactobacillus gasseri 0LL2959. Furthermore, the present inventors prepared yogurt using the above-mentioned lactic acid bacteria to confirm that the above-mentioned lactic acid bacteria are suitable for processing foods including yogurt. Since the lactic acid bacteria of the present invention suppress the increase of serum uric acid levels, they can be used effectively as pharmaceuticals for preventing or treating hyperuricemia or gout. Furthermore, since it has been confirmed by experiments that the lactic acid bacteria of the present invention
[Patent Document 111 WO 2004/112809 [Non-patent Document 1] Homepage of the Japan Society for Bioscience, Biotechnology, and Agrochemistry (JSBBA), Annual Meeting of JSBBA Lecture and Presentation Database (http://jsbba.bioweb.ne.jp/jsbba_db/index.html) "JSBBA 2004.03.30 general lecture, Ikenaga, T., Kumemura, M. et al.: Effects of lactic acid bacteria on the blood uric acid levels of dietary hyperuricemia model rats"
Disclosure of the Invention The present invention may provide lactic acid bacteria that are capable of preventing and/or treating hyperuricemia, which are suitable for use in dietary products or pharmaceuticals, and at the same time to provide compositions that use the above-mentioned lactic acid bacteria for preventing and/or treating hyperuricemia.
The present inventors persistently made dedicated efforts to arrive at the present invention. First, various lactic acid bacteria were cultured in the presence of inosine and guanosine, and the amount of the above-mentioned nucleosides consumed and the amount of degradation products (hypoxanthine and guanine) produced were determined.
Then, several lactic acid bacteria with remarkable nucleoside-decomposing ability were selected. Lactic acid bacteria assessed to have high nucleoside-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and the serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on the serum uric acid level was examined. As a result, lactic acid bacteria which significantly suppress the increase of serum uric acid level were found:
Lactobacillus oris 0LL2779 and Lactobacillus gasseri 0LL2959. Furthermore, the present inventors prepared yogurt using the above-mentioned lactic acid bacteria to confirm that the above-mentioned lactic acid bacteria are suitable for processing foods including yogurt. Since the lactic acid bacteria of the present invention suppress the increase of serum uric acid levels, they can be used effectively as pharmaceuticals for preventing or treating hyperuricemia or gout. Furthermore, since it has been confirmed by experiments that the lactic acid bacteria of the present invention
3 have the effect of suppressing the increase of serum uric acid levels through oral administration and are suitable for actual food processing, their applicability is remarkably high because they can be used as food. Thus, the present invention relates to lactic acid bacteria capable of preventing and/or treating hyperuricemia and uses thereof. Specifically, the present invention provides the following:
[1] a lactic acid bacterium of the genus Lactobacillus, wherein the bacterium has purine-decomposing ability but not gas-producing ability;
[2] the lactic acid bacterium of [1] described above, wherein the bacterium is Lactobacillus gasseri;
[3] a lactic acid bacterium Lactobacillus oris, wherein the bacterium has purine-decomposing ability;
[1] a lactic acid bacterium of the genus Lactobacillus, wherein the bacterium has purine-decomposing ability but not gas-producing ability;
[2] the lactic acid bacterium of [1] described above, wherein the bacterium is Lactobacillus gasseri;
[3] a lactic acid bacterium Lactobacillus oris, wherein the bacterium has purine-decomposing ability;
[4] the lactic acid bacterium of the genus Lactobacillus of [2] described above, wherein the bacterium is Lactobacillus gasseri 0LL2959 (Accession No.: NITE BP-224);
[5] the lactic acid bacterium of the genus Lactobacillus of [3] described above, wherein the bacterium is Lactobacillus oris 0LL2779 (Accession No.: NITE BP-223);
[6] a dietary product for suppressing an increase in blood uric acid level, which comprises the lactic acid bacterium of any one of [1] to [5] described above, a substance containing said lactic acid bacterium, and/or a processed material thereof;
[7] a pharmaceutical for suppressing an increase in blood uric acid level, which comprises the lactic acid bacterium of any one of [1] to [5] described above, a substance containing said lactic acid bacterium, and/or a processed material thereof;
[8] a pharmaceutical for preventing and/or treating hyperuricemia, which comprises the lactic acid bacterium of any one of [1] to [5] described above, a substance containing said lactic acid bacterium, and/or a processed material thereof;
[9] a dietary product for preventing and/or treating hyperuricemia, which comprises the lactic acid bacterium of any one of [1] to [5] described above, a substance containing said lactic acid bacterium, and/or a processed material thereof;
[10] a method for suppressing the level of purine ingested from food, wherein the method comprises administering the lactic acid bacterium of any one of [1] to [5]
described above, a substance containing said lactic acid bacterium, and/or a processed material thereof;
described above, a substance containing said lactic acid bacterium, and/or a processed material thereof;
[11] a method for suppressing an increase in blood uric acid level, wherein the method comprises administering the lactic acid bacterium of any one of [1] to [5]
described above, a substance containing said lactic acid bacterium, and/or a processed material thereof;
described above, a substance containing said lactic acid bacterium, and/or a processed material thereof;
[12] a method for producing a dietary product with reduced purine level, wherein the method comprises the step of contacting a raw material or intermediate product of the dietary product with the lactic acid bacterium of any one of [1] to [5] described above, a substance containing said lactic acid bacterium, and/or a processed material thereof;
[13] a method for treating and/or preventing any one or more diseases or symptoms from the group consisting of hyperuricemia, gout, renal dysfunction, urolithiasis, and arteriosclerosis, wherein the method comprises administering the lactic acid bacterium of any one of [1] to [5]
described above, a substance containing said lactic acid bacterium, and/or a processed material thereof; and
described above, a substance containing said lactic acid bacterium, and/or a processed material thereof; and
[14] use of the lactic acid bacterium of any one of [1] to [5] described above, a substance containing said lactic acid bacterium, and/or a processed material thereof in the manufacture of a dietary product and/or pharmaceutical for suppressing an increase in blood uric acid level in a subject of administration.
In one aspect, the invention provides a lactic acid bacterium Lactobacillus oris 0LL2779 (Accession No.: NITE BP-223).
In another aspect, the invention provides a dietary product comprising one or both of this lactic acid bacterium and a substance containing this lactic acid bacterium.
In another aspect, the invention provides a pharmaceutical composition comprising one or both of this lactic acid bacterium and a substance containing this lactic acid bacterium, together with a pharmaceutically acceptable carrier.
In another aspect, the invention provides use of this lactic acid bacterium, a substance containing this lactic acid bacterium, or a combination thereof, in the manufacture of a dietary product or a pharmaceutical composition for preventing or treating, in a subject, one or more diseases or symptoms selected from the group consisting of hyperuricemia, gout, renal dysfunction, urinary stone, and arteriosclerosis.
In another aspect, the invention provides use of this lactic acid bacterium, a substance containing this lactic acid bacterium, or a combination thereof, or the dietary product of the invention or the pharmaceutical composition of the invention, for preventing or treating, in a subject, one or more diseases or symptoms selected from the group consisting of hyperuricemia, gout, renal dysfunction, urinary stone, and arteriosclerosis.
4a In another aspect, the invention provides a method for producing a dietary product with reduced purine level, wherein the method comprises the step of contacting a raw material or intermediate product of the dietary product with one or more of this lactic acid bacterium, a substance containing said lactic acid bacterium, and a processed material thereof.
Brief Description of the Drawings Fig. 1 shows the purine-decomposing ability of each of the lactic acid bacteria when they were cultured in the presence of a purine (inosine). Bacterial strains confirmed to have high purine-degradation rate (indicated with stars) were used. as subjects of animal model experiment.
Fig. 2 shows the purine-decomposing ability of each of the lactic acid bacteria when they were cultured in the presence of a purine (guanosine). Bacterial strains confirmed to have high purine-degradation rate (indicated with stars) were used as subjects of animal model experiment.
Fig. 3 shows evaluation of the purine-decomposing ability of lactic acid bacteria L.
,fermenttan and L. brevis by (amount of hypoxanthine + amount of guanine) /
amount of 5-bromouracil.
Fig. 4 shows the results of orally administering lactic acid bacteria (L.
fermentum and L.
brevis) with high purine-decomposing ability to dietary hyperuricemia model animals, and measuring the serum uric acid level.
Fig. 5 shows the results of orally administering lactic acid bacteria (L. oris and L. gasseri) with high purine-decomposing ability to dietary hyperuricemia model animals, and measuring the serum uric acid level. Significant suppression of the increase in serum uric acid levels was observed on day 2 and day 5 after start of administration in the L. oris 0LL2779 strain-administered group (Group 7), and on day 5 after start of administration in the L. gasseri 0LL2959 strain-administered group (Group 9) (# in the figure).
4b Best Mode for Carrying Out the Invention The present invention relates to lactic acid bacteria of the genus Lactobacillus that have purine-decomposing ability and not gas-producing ability. The present invention is based on the present inventors' initial discovery of lactic acid bacteria of the genus Lactobacillus that have purine-decomposing ability and not gas-producing ability (hereinafter also referred to as "lactic acid bacteria of the genus Lactobacillus of the present invention").
The genus Lactobacillus is one of the representative genera of lactic acid bacteria, and 5 includes 80 or more species. Examples of species included in Lactobacillus are Lactobacillus delbrueckii subsp. burgalicus, Lactobacillus delbrueckii subsp. lactis, Lactobacillus paracasei subsp. paracasei, Lactobacillus helveticus, Lactobacillus helveticus subsp.
jugurti, Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus amylovorus, Lactobacillus gallinarum, Lactobacillus gasseri, Lactobacillus oris, Lactobacillus casei subsp.
rhamnosus, Lactobacillus johnsonii, Lactobacillus fermentum, and Lactobacillus brevis. The lactic acid bacteria of the genus Lactobacillus of the present invention may be any species as long as they are lactic acid bacteria of the genus Lactobacillus that have purine-decomposing ability and not gas-producing ability, and they are preferably Lactobacillus gasseri.
Purines are components that constitute nucleic acids, and they are supplied to the living body through de novo purine synthesis, salvage pathway, nucleoproteins in the diet, and such, and unnecessary purines are metabolized in the liver and then excreted. Uric acid is the final metabolite of purines in humans, higher primates, birds, reptiles, and such.
Herein, purines are compounds that comprise a purine skeleton. Representative examples of purines include purine nucleotides (adenylic acid, deoxyadenylic acid, guanylic acid, and deoxyguanylic acid), purine nucleosides (adenosine, deoxyadenosine, guanosine, and deoxyguanosine), purine bases (adenine and guanine), and oligonucleotides and polynucleotides comprising purine bases. Purine bases constitute, besides nucleic acids, a wide variety of biological components such as ATP, GTP, cAMP, cGMP, coenzyme A, FAD, and NAD.
All of such biological components are also included in the purines herein as long as they comprise a purine skeleton.
Purines in a living body are metabolized to uric acid. The metabolic pathways from purines to uric acid are well known. 5'-Nucleotidase converts AMP to adenosine which is converted to hypoxanthine via inosine. 5'-Nucleotidase converts GMP to guanosine which then becomes guanine. Hypoxanthine and guanine are metabolized by xanthine oxidase and guanine deaminase, respectively, both giving xanthine, and xanthine oxidase further converts xanthine to uric acid.
Purine-decomposing ability in the present invention refers to the ability to decompose at least one purine, regardless of whether the degradation product comprises a purine skeleton.
Thus, the ability to decompose a certain purine into a compound that does not comprise a purine skeleton, and the ability to decompose a certain purine to form a different purine (a compound comprising a purine skeleton) are both included in the purine-decomposing ability of the present invention.
Lactic acid bacteria of the genus Lactobacillus of the present invention can be separated by known methods. For example, they can be isolated by culturing bacteria obtained from the feces of mammals such as humans, separating Lactobacillus based on the form, physiological characteristics, and such of the cultured bacteria; detecting the presence or absence of purine-decomposing ability and gas-producing ability; and then selecting Lactobacillus which has purine-decomposing ability but not gas-producing ability. Detection of purine-decomposing ability and gas-producing ability can be performed by known methods, and as an example, they can be performed by the methods in the Examples.
Media that are generally suitable for culturing lactic acid bacilli may be used for culturing the lactic acid bacteria of the genus Lactobacillus of the present invention, and media comprising carbon sources such as glucose, lactose, galactose, fructose, trehalose, sucrose, mannose, and cellobiose; nitrogen sources such as meat extracts, peptone, yeast extracts, casein, and whey proteins; and inorganic nutrients such as magnesium sulfate, iron sulfate, and manganese sulfate can be used. One preferable example includes Lactobacilli MRS Broth (Difco). The culture conditions are not particularly restricted, as long as the growth of intestinal lactobacilli is possible. Preferable conditions include, for example, pH5.0 to pH8.0, and temperature of 20 C to 45 C, and more preferable conditions are anaerobic, pH5.0 to pH7.0, and temperature of 30 C to 40 C.
As described later, the present inventors orally administered the lactic acid bacteria of the genus Lactobacillus of the present invention to model animals, and confirmed that these lactic acid bacteria have an effect of suppressing the increase of blood uric acid levels.
Therefore, lactic acid bacteria of the genus Lactobacillus of the present invention can be used to suppress the increase in blood uric acid levels or prevent and/or treat hyperuricemia.
Furthermore, it may be possible to manufacture foods that contain a reduced amount of purines using the purine-decomposing ability of the lactic acid bacteria of the genus Lactobacillus of the present invention.
Specific examples of "lactic acid bacteria of the genus Lactobacillus having purine-decomposing ability but not gas-producing ability" in the present invention include Lactobacillus gasseri 0LL2959 specified by Accession No.: NITE BP-224. The present inventors examined the presence or absence of purine-decomposing ability and gas-producing ability for a large number of lactic acid bacteria, and specifically found that the lactic acid bacteria of the genus Lactobacillus named Lactobacillus gasseri 0LL2959 has purine-decomposing ability but not gas-producing ability. Furthermore, they determined through in vivo experiments that Lactobacillus gasseri 0LL2959 significantly suppresses the increase in blood uric acid level. The present inventors deposited the above-mentioned bacterial strain with the Patent Microorganisms Depositary (NPMD) of the National Institute of Technology and Evaluation. Contents specifying the deposit are described below.
(A) Depositary institution: Patent Microorganisms Depositary (NPMD) of the National Institute of Technology and Evaluation (Location: 2-5-8, Kazusakamatari, Kisarazu-city, Chiba, 292-0818, Japan) (B) Original date of deposition: March 31, 2006 Date of transfer from domestic deposit to deposit under the Budapest Treaty:
November 21, 2007 (C) Accession No.:
Lactobacillus gasseri strain 0LL2959 (Accession No.: NITE BP-224) Furthermore, the present invention relates to Lactobacillus oris (lactic acid bacteria) which has purine-decomposing ability. The present invention is based on the present inventors' initial discovery of lactic acid bacteria Lactobacillus oris which have purine-decomposing ability (hereinafter, also referred to as "lactic acid bacteria Lactobacillus oris of the present invention").
Lactobacillus oris (lactic acid bacteria) of the present invention can be separated and cultured by a method similar to the above-described method for separation and culture of lactic acid bacteria of the genus Lactobacillus of the present invention.
Furthermore, lactic acid bacteria Lactobacillus oris of the present invention can also be used for suppressing the increase in blood uric acid levels, or prevention and/or treatment of hyperuricemia.
Specific examples of "Lactobacillus oris (lactic acid bacteria) with purine-decomposing ability" of the present invention include Lactobacillus oris 0LL2779 specified by Accession No.: NITE BP-223. From a large number of lactic acid bacteria, the present inventors found Lactobacillus oris 0LL2779 as a lactic acid bacterium having purine-decomposing ability, and discovered through in vivo experiments that Lactobacillus oris 0LL2779 significantly suppresses the increase in blood uric acid levels. The present inventors deposited the above-mentioned bacterial strain with the Patent Microorganisms Depositary (NPMD) of the National Institute of Technology and Evaluation. Contents specifying the deposit are described below.
(A) Depositary institution: Patent Microorganisms Depositary (NPMD) of the National Institute of Technology and Evaluation (Location: 2-5-8, Kazusalcamatari, Kisarazu-city, Chiba, 292-0818, Japan) (B) Original date of deposition: March 31, 2006 Date of transfer from domestic deposit to deposit under the Budapest Treaty:
November 21, 2007 (C) Accession No.:
Lactobacillus oris strain 0LL2779 (Accession No.: NITE BP-223) Lactic acid bacteria of the genus Lactobacillus of the present invention and lactic acid bacteria Lactobacillus oris of the present invention can be used to manufacture dietary products or pharmaceuticals for suppressing the increase in blood uric acid levels, and dietary products or pharmaceuticals for preventing and/or treating hyperuricemia.
Dietary products prepared using the lactic acid bacteria of the genus Lactobacillus of the present invention and lactic acid bacteria Lactobacillus oris of the present invention are not limited in terms of their category or type and may be functional food, specified health food, health food, nursing care food, or may be dairy products such as confectionary, lactic acid bacteria beverage, cheese, or yogurt, flavoring agents, or such. The form of the dietary product is also not limited, and may take the form of any dietary product that may be commonly distributed such as a solid, liquid, fluid diet, jelly, tablets, granules, or capsules. The above-mentioned dietary products can be manufactured through methods that are ordinary to those skilled in the art. In producing the above-mentioned dietary products, carbohydrates, proteins, lipids, dietary fibers, vitamins, biologically essential trace metals (manganese sulfate, zinc sulfate, magnesium chloride, potassium carbonate, etc.), flavors, or other compositions may be added, as long as they do not interfere with the growth of lactic acid bacteria.
The lactic acid bacteria of the genus Lactobacillus of the present invention and lactic acid bacteria Lactobacillus oris of the present invention, material containing these lactic acid bacteria and/or processed material thereof (for example, culture, concentrate, paste material, spray-dried material, freeze-dried material, vacuum-dried material, drum-dried material, fluid material, dilution material, and homogenate) can be processed into common dietary products comprising dairy products/fermented milk as described above, and used as starters for producing dairy products/fermented milk such as yogurt and cheese. When they are used as starters, other microorganisms may be admixed as long as they do not interfere with the manufacturing of dairy products or the inhabitation/proliferation of the lactic acid bacteria of the genus Lactobacillus of the present invention and lactic acid bacteria Lactobacillus oris of the present invention. For example, they may be admixed with Lactobacillus delbruekii subsp. bulgaricus, Streptococcus thermophilus, or Lactobacillus acidophilus which are major bacterial species of lactic acid bacteria in yogurt, and additionally, they may be admixed with bacterial species generally used for yogurt or cheese and made into starters. Dairy products and fermented milk can be manufactured using the above-mentioned starters by ordinary methods. For example, plain yogurt can be manufactured by admixing the above-mentioned starter with milk or dairy products that have been subjected to heating, mixing, homogenization, sterilization treatment, and cooling, followed by fermentation and cooling.
The lactic acid bacteria of the genus Lactobacillus of the present invention and lactic acid bacteria Lactobacillus oris of the present invention can be admixed with physiologically acceptable carriers, excipients, diluting agents, or such, and administered orally or parenterally as pharmaceutical compositions; however, the preferred method of administration is oral administration. Formulations for oral administration can be prepared as various well-known dosage forms, and such examples include granules, powders, tablets, pills, capsules, liquids, syrups, emulsions, suspensions, and troches. Furthermore, by preparing an enteric-coated formulation by methods well-known to those skilled in the art, the lactic acid bacteria of the genus Lactobacillus of the present invention can be transported efficiently to the intestine without being affected by gastric acid.
Pharmaceuticals and dietary products manufactured using the lactic acid bacteria of the genus Lactobacillus of the present invention and lactic acid bacteria Lactobacillus oris of the present invention can be expected to display an effect of suppressing the increase in blood uric acid levels or an effect of preventing and/or treating hyperuricemia through the actions of these bacteria in the dietary products.
Furthermore, by using the purine-decomposing ability of the lactic acid bacteria of the genus Lactobacillus of the present invention and lactic acid bacteria Lactobacillus oris of the present invention, dietary products with reduced purine levels can also be manufactured.
Methods of the present invention for manufacturing dietary products with reduced purine levels comprise the step of contacting the lactic acid bacteria of the genus Lactobacillus of the present invention and lactic acid bacteria Lactobacillus oris of the present invention with a raw material or intermediate product of the dietary product. This step efficiently reduces the amount of purine contained in the raw materials or intermediate products. The above-mentioned step is preferably carried out under conditions in which the lactic acid bacteria of the genus Lactobacillus of the present invention and lactic acid bacteria Lactobacillus oris of the present invention are viable. In addition to the above-mentioned step, the manufacturing method of the present invention may comprise common steps for manufacturing dietary products of interest such as a crushing step, admixing step, drying step, sterilization step, and packing step. Dietary products manufactured by the methods of the present invention are not limited in terms of their category or type and may be, for example, functional food, specified health food, health food, nursing care food, or common food, for example, food categorized as tasty food; however, they are particularly useful as a daily dietary product or supplementary dietary product for patients with a disease or symptom that requires limiting purine intake, or the high-risk group for the above-mentioned disease or symptoms. The methods of the present invention enable people who need to limit their purine intake or people who want to control their purine intake to consume foods normally high in purine level and enjoy their nutrients or taste.
Examples Herein below, the present invention will be specifically described with reference to the Examples, but it is not to be construed as being limited thereto. In the Examples, the bacterial strains indicated as JCM in the bacterial strain name are standard strains obtained from the Japan Collection of Microorganisms RIKEN BioResource Center, the bacterial strains indicated as ATCC in the bacterial strain name are standard strains obtained from the American Type Culture 5 Collection, and the bacterial strains indicated as MEP in the bacterial strain name are bacterial strains held by Meiji Dairies Corporation.
[Example 1] In vitro experiment method on the uric acid-reducing effect of lactic acid bacteria The following method was used to examine the presence or absence of 10 purine-decomposing ability in each type of lactic acid bacteria.
Using a Difco Lactobacilli MRS Broth (manufactured by BD) medium, each type of lactic acid bacteria (bacterial cells) was placed in a sealed container with an oxygen adsorbing agent "AnaeroPack" (manufactured by Mitsubishi Gas Co.) and anaerobically cultured overnight at a temperature of 37 C. The bacterial suspension solution obtained after culturing was subjected to centrifugal separation at a rotation frequency of 3000 rpm for 10 minutes at a temperature of 4 C to precipitate and collect (harvest) the bacterial cells.
A lx 109 CFU/mL bacterial cell suspension solution was prepared from these bacterial cells using a 0.1 M sodium phosphate buffer.
After preparing the various types of bacterial cell suspension solutions, inosine and guanosine were each added at 1.25 mM to every bacterial cell suspension solution. These bacterial cell suspension solutions were placed in a 37 C constant temperature bath, and then shake cultured at a horizontal rotation frequency of 140 rpm for 30 minutes or two hours.
The consumption level of nucleosides and the production level of bases (hypoxanthine and guanine), which are degradation products of nucleosides, in the shake cultured bacterial cell suspension solutions (reaction solutions) were measured on HPLC using 5-bromouracil as the internal standard. 200 gL of the reaction solution was added to 780 pL of mobile phase A, and 20 gL of 5-bromouracil (1.6 mg/mL) was added as the internal standard and mixed. This mixed solution was filtered with a filter (pore size 0.45 gm), and then 501.11. of the filtered solution was injected into HPLC. The specific operational conditions of the HPLC are as follows.
HPLC: Waters alliance 2690 Column: CAPCELL PAK C18 SG120, particle diameter 5 gm, column size 4.6 x 250 mm (Shiseido) Mobile phase: A: 25 mM KH2PO4 (0.1% methanol) B: 25 mM KH2PO4 (0.1% methanol)/methanol (75:25) gradient A/B (min): 100/0 (0) - 100/0 (10) - 20/80 (20) - 20/80 (25) -100/0 (26) - 100/0 (40) Detector: photodiode array (Waters 996) detection wavelength of 254 nm Flow rate: 1 mL/min Column temperature: room temperature The results are shown in Figs. 1 to 3. Each compound was quantified based on the peak area values in the HPLC chart. Furthermore, the degradation rates for Figs. 1 and 2 were calculated according to the following equation:
Degradation rate = 100 - (amount of inosine or guanosine / amount of inosine or guanosine in the blank) x 100.
The calculation method for Fig. 3 is as follows:
(amount of hypoxanthine + amount of guanine) / amount of 5-bromouracil Based on the results of Figs. 1 to 3, lactic acid bacteria assessed to have remarkable nucleoside-decomposing ability were selected.
[Example 2] In vivo experiment method on the uric acid-reducing effect of lactic acid bacteria Dietary hypertuicemia model animals were produced according to the method described in prior literature (Non-patent Document 1), and the effects of microorganisms (lactic acid bacteria) on the animals' serum uric acid levels were examined. Specifically, the above-mentioned method is a method that prepares a mixed feed containing 2.5 weight %
potassium oxonate and 1.0 weight % RNA, feeds rats with the mix, and compares the post-intake blood uric acid levels with those of the negative group and the control group.
It has been found that when the model animals in this method are given an oral administration of allopurinol which is an inhibitor of uric acid production, the blood uric acid level in the model animals is significantly suppressed ("Shokuhin kinou kenkyu News (Food Function Research News)" vol.
14, March, 9, 2005 issue, Mercian Cleantec Co. environmental inspection center, http://www.m-cleantec.com/gizyutu/news_0503.html). This indicates that the above-mentioned method is useful as a system for evaluating the effectiveness of foods against hyperuricemia.
[2-1 Materials and Experimental Procedure]
[Microorganisms]
Five strains, Lactobacillus fermentum strain MEP181504 (hereinafter, "Lactobacillus"
will be abbreviated as "L." in some cases), L. brevis strain MEP181507, L.
gasseri strain JCM8787, L. gasseri strain 0LL2959, and L. oris strain 0LL2779, which were assessed to have high nucleoside-decomposing ability in the above-mentioned in vitro experiment, were used.
Bacterial cell suspension solutions were prepared from these various lactic acid bacteria in the same manner as in the in vitro experiments. The bacterial cell suspension solutions were orally administered to rats at 1 x 109 CFU/10 mL/kg.
[Experimental animals]
Rats (Wister SPF, male, 7 weeks old) were used. Plastic cages for rats were used for rearing (habituation and testing), and a single rat was housed in each cage.
The light-dark cycle was light from 7 a.m. to 7 p.m. (12 hours).
[Preliminary rearing (taming) and group division]
Experimental animals went through a one-week preliminary rearing (habituation) after they were brought in. During habituation, the animals were allowed to freely consume AIN-93G (Oriental Yeast Co. Ltd.) as feed (food) and tap water as drinking water. After preliminary rearing, blood was collected through the tail vein of rats (seven days after arrival, 8 weeks old, day 0) in a non-fasting state in the morning. This blood was left at room temperature for 30 minutes or more, then serum was fractionated by centrifugal separation at a rotation frequency of 10,000 rpm for 10 minutes, and then the uric acid level in the serum was measured using the phosphotungstic acid method.
Groups were divided such that the serum uric acid level in each group was the same.
A total of nine groups with five rats in each group were used in the test:
negative groups (Groups 1 and 5), control groups (Groups 2 and 6), and bacterial cell-administered groups (Groups 3, 4, and 7 to 9). The names of the groups, feed, administered substance (administration dose), number of animals, and such are indicated below.
- Negative groups (Groups 1 and 5): "AIN-93G" as feed, "physiological saline"
was administered (10 mL/kg), five animals.
- Control groups (Groups 2 and 6): "A1N-93G admixed with 2.5 weight %
potassium oxonate and 1.0 weight % RNA" as feed, "physiological saline" was administered (10 mL/kg), five animals.
- Bacterial cell-administered group (Groups 3, 4, and 7 to 9): in each group, "AIN-93G admixed with 2.5 weight % potassium oxonate and 1.0 weight % RNA" as feed, five animals. The administered bacterial cells and doses for each of the groups are as follows:
for Group 3, "a suspension solution of L. fermentum strain MEP181504 (1 x 108 CFU/mL)" was administered (10 mL/kg), for Group 4, "a suspension solution of L. brevis strain MEP181507 (1 x 108 CFU/mL)" was administered (10 mL/kg), for Group 7, "a suspension solution of L. oris strain 0LL2779 (1 x 108 CFU/mL)" was administered (10 mL/kg), for Group 8, "a suspension solution of L. gasseri strain JCM8787 (1 x 108 CFU/mL)" was administered (10 mL/kg), for Group 9, "a suspension solution of L. gasseri strain 0LL2959 (1 x 108 CFU/mL)" was administered (10 mL/kg).
[Main breeding (test)]
The test period was set to be eight days from the day after group division, and each of the "AIN-93G" feed (negative groups) and "AIN-93G + potassium oxonate + RNA"
feed (control groups and bacterial cell-administered groups) were freely fed to the rats using a diet feeder. The start date of feeding the main feed was set to Day 1, and the subsequent days were counted from this date. The "AIN-93G + potassium oxonate + RNA" feed comprises 2.5 weight % potassium oxonate (100 g, ALDRICH) and 1.0 weight % RNA (500 g, MP
Biomedicals Inc.). 1 x 109 CFU/10 mL/kg of the aforementioned bacterial cell suspension was orally administered by force to the experimental animals of the bacterial cell-administered groups. To the negative groups and control groups, 10 mL/kg of physiological saline solution instead of the bacterial cell suspension was orally administered by force.
[Measurement, examination, and such]
- Observation of the general status and measurement of body weight In all cases (all groups), the general status was observed at the time of administration every day from day 1 to day 8, and the body weight was measured at a fixed time between 9 a.m.
and 10 a.m. on days 0, 1, 5, and 8.
- Measurement of feed consumption and water consumption In all cases (all groups), feed consumption and water consumption were measured at a fixed time between 9 a.m. and 10 a.m. on day 1 (set level), day 5 (residual level, set level), and day 8 (residual level).
- Blood collection and biochemical tests In all cases (all groups), blood was collected from the tail vein on day 0 (in the morning), day 2 (one hour after administration), day 5 (one hour after administration), and day 8 (before administration). The collected blood was subjected to centrifugal separation at a rotation frequency of 10,000 rpm for ten minutes to fractionate the serum, and the uric acid level in the serum was measured by the phosphotungstic acid method. As described above, the serum uric acid levels measured on day 0 were used for group division.
- Autopsy and biochemical tests In all cases (all groups), blood collection from the tail vein on day 8 was followed by oral administration of the bacterial cell suspension solution. One hour after administration, whole blood was collected from the abdominal aorta under nembutal (pentobarbital 40 mg/kg) anesthesia and the animal died. The collected blood was centrifuged at a rotation frequency of 3000 rpm for 15 minutes to fractionate the serum, and then creatinine, uric acid, and urea nitrogen in the serum were measured.
- Measurement of organ weight The liver was excised from the rat, and its wet weight was measured.
[Statistical processing]
The results are indicated as the mean standard deviation, and the control groups were compared with each of the bacterial cell-administered groups. Variance ratios of the numerically converted test values were tested by the F test, Student's t-test was used in the case of equal variance, and Aspin-Welch t-test was used in the case of unequal variance. The statistical analysis of Excel Statistics 2004 was used for statistical processing, and the lowest level of significance was set to 5% on both sides.
[2-2 Results]
The results of the general status are shown in Table 1 (L. fermentum and L.
brevis) and Table 2 (L. oris and L. gasseri), and the changes in serum uric acid levels are shown in Figs. 4 and 5.
As shown in Fig. 5, significant difference in the reduction of serum uric acid level as a result of administration of each type of lactic acid bacteria was observed in the L. oris 0LL2779-administered group and the L. gasseri 0LL2959-administered group. In terms of general status, there were no problems with the kidney function (creatinine values, serum urea nitrogen, and kidney weight), or body weight, feed consumption, and water consumption in any of the groups. Furthermore, no significant difference in the general status observed was found among the various types of lactic acid bacteria. The scientific characteristics of L. oris 0LL2779 and L. gasseri 0LL2959 are shown in Table 3.
=
cr AMOUNT OF BODY WEIGHT INCREASE
28.6 2.3 23.0 -1- 2.9 20.0 -1- 3.5 20.0 3.7 DURING THE TESTING PERIOD (g) FEED CONSUMPTION
DURING THE TESTING PERIOD (g) 106.9 7.7 88.2 -1- 3.9 82.7 - 4.2 85.1 6.3 WATER COMSUMPTION 96.7 -I- 15.1 192.2 I- 11.9 183.3 -1-12.7 190.8 16.7 DURING THE TESTING PERIOD (g) SERUM CREATININE LEVEL 0.7 0.1 0.8 0.1 0.8 0.1 0.8 0.0 (DAY 8) (mg/dL) AMOUNT OF SERUM UREA NITROGEN 15.5 1.5 15.2 -I- 2.4 16.3 2.0 14.8 1.7 (DAY 8) (mg/dL) ABSOLUTE KIDNEY WEIGHT
(DAY 8) (g) 1.5 0.1 1.6 0.0 1.6 0.1 1.6 -I- 0.1 o CO
o CO
o 1-`
o o CO
cr AMOUNT OF BODY WEIGHT INCREASE
DURING THE TESTING PERIOD (g) 29.2 2.8 18.4 7.3 19.2 1.4 18.6 4.0 21.3 4.5 FEED CONSUMPTION
DURING THE TESTING PERIOD (g) 102.8 7.4 87.6 4.7 87.8 4.4 94.4 12.3 87.9 6.7 WATER COMSUMPT I ON
DURING THE TESTING PERIOD (g) 108-0 13-0 17" 15-3 173.0 134 183.6 8.1 168.2 - 13.1 SERUM GREAT I N I NE LEVEL
(DAY 8) (mg/dL) 0.7 - 0.0 0.8 0.1 0.7 0.0 0.7 0.1 0.7 0.0 SERUM UREA NITROGEN LEVEL
(DAY 8) (mg/dL) 14.5 1.1 14.5 2.0 13.5 0.7
In one aspect, the invention provides a lactic acid bacterium Lactobacillus oris 0LL2779 (Accession No.: NITE BP-223).
In another aspect, the invention provides a dietary product comprising one or both of this lactic acid bacterium and a substance containing this lactic acid bacterium.
In another aspect, the invention provides a pharmaceutical composition comprising one or both of this lactic acid bacterium and a substance containing this lactic acid bacterium, together with a pharmaceutically acceptable carrier.
In another aspect, the invention provides use of this lactic acid bacterium, a substance containing this lactic acid bacterium, or a combination thereof, in the manufacture of a dietary product or a pharmaceutical composition for preventing or treating, in a subject, one or more diseases or symptoms selected from the group consisting of hyperuricemia, gout, renal dysfunction, urinary stone, and arteriosclerosis.
In another aspect, the invention provides use of this lactic acid bacterium, a substance containing this lactic acid bacterium, or a combination thereof, or the dietary product of the invention or the pharmaceutical composition of the invention, for preventing or treating, in a subject, one or more diseases or symptoms selected from the group consisting of hyperuricemia, gout, renal dysfunction, urinary stone, and arteriosclerosis.
4a In another aspect, the invention provides a method for producing a dietary product with reduced purine level, wherein the method comprises the step of contacting a raw material or intermediate product of the dietary product with one or more of this lactic acid bacterium, a substance containing said lactic acid bacterium, and a processed material thereof.
Brief Description of the Drawings Fig. 1 shows the purine-decomposing ability of each of the lactic acid bacteria when they were cultured in the presence of a purine (inosine). Bacterial strains confirmed to have high purine-degradation rate (indicated with stars) were used. as subjects of animal model experiment.
Fig. 2 shows the purine-decomposing ability of each of the lactic acid bacteria when they were cultured in the presence of a purine (guanosine). Bacterial strains confirmed to have high purine-degradation rate (indicated with stars) were used as subjects of animal model experiment.
Fig. 3 shows evaluation of the purine-decomposing ability of lactic acid bacteria L.
,fermenttan and L. brevis by (amount of hypoxanthine + amount of guanine) /
amount of 5-bromouracil.
Fig. 4 shows the results of orally administering lactic acid bacteria (L.
fermentum and L.
brevis) with high purine-decomposing ability to dietary hyperuricemia model animals, and measuring the serum uric acid level.
Fig. 5 shows the results of orally administering lactic acid bacteria (L. oris and L. gasseri) with high purine-decomposing ability to dietary hyperuricemia model animals, and measuring the serum uric acid level. Significant suppression of the increase in serum uric acid levels was observed on day 2 and day 5 after start of administration in the L. oris 0LL2779 strain-administered group (Group 7), and on day 5 after start of administration in the L. gasseri 0LL2959 strain-administered group (Group 9) (# in the figure).
4b Best Mode for Carrying Out the Invention The present invention relates to lactic acid bacteria of the genus Lactobacillus that have purine-decomposing ability and not gas-producing ability. The present invention is based on the present inventors' initial discovery of lactic acid bacteria of the genus Lactobacillus that have purine-decomposing ability and not gas-producing ability (hereinafter also referred to as "lactic acid bacteria of the genus Lactobacillus of the present invention").
The genus Lactobacillus is one of the representative genera of lactic acid bacteria, and 5 includes 80 or more species. Examples of species included in Lactobacillus are Lactobacillus delbrueckii subsp. burgalicus, Lactobacillus delbrueckii subsp. lactis, Lactobacillus paracasei subsp. paracasei, Lactobacillus helveticus, Lactobacillus helveticus subsp.
jugurti, Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus amylovorus, Lactobacillus gallinarum, Lactobacillus gasseri, Lactobacillus oris, Lactobacillus casei subsp.
rhamnosus, Lactobacillus johnsonii, Lactobacillus fermentum, and Lactobacillus brevis. The lactic acid bacteria of the genus Lactobacillus of the present invention may be any species as long as they are lactic acid bacteria of the genus Lactobacillus that have purine-decomposing ability and not gas-producing ability, and they are preferably Lactobacillus gasseri.
Purines are components that constitute nucleic acids, and they are supplied to the living body through de novo purine synthesis, salvage pathway, nucleoproteins in the diet, and such, and unnecessary purines are metabolized in the liver and then excreted. Uric acid is the final metabolite of purines in humans, higher primates, birds, reptiles, and such.
Herein, purines are compounds that comprise a purine skeleton. Representative examples of purines include purine nucleotides (adenylic acid, deoxyadenylic acid, guanylic acid, and deoxyguanylic acid), purine nucleosides (adenosine, deoxyadenosine, guanosine, and deoxyguanosine), purine bases (adenine and guanine), and oligonucleotides and polynucleotides comprising purine bases. Purine bases constitute, besides nucleic acids, a wide variety of biological components such as ATP, GTP, cAMP, cGMP, coenzyme A, FAD, and NAD.
All of such biological components are also included in the purines herein as long as they comprise a purine skeleton.
Purines in a living body are metabolized to uric acid. The metabolic pathways from purines to uric acid are well known. 5'-Nucleotidase converts AMP to adenosine which is converted to hypoxanthine via inosine. 5'-Nucleotidase converts GMP to guanosine which then becomes guanine. Hypoxanthine and guanine are metabolized by xanthine oxidase and guanine deaminase, respectively, both giving xanthine, and xanthine oxidase further converts xanthine to uric acid.
Purine-decomposing ability in the present invention refers to the ability to decompose at least one purine, regardless of whether the degradation product comprises a purine skeleton.
Thus, the ability to decompose a certain purine into a compound that does not comprise a purine skeleton, and the ability to decompose a certain purine to form a different purine (a compound comprising a purine skeleton) are both included in the purine-decomposing ability of the present invention.
Lactic acid bacteria of the genus Lactobacillus of the present invention can be separated by known methods. For example, they can be isolated by culturing bacteria obtained from the feces of mammals such as humans, separating Lactobacillus based on the form, physiological characteristics, and such of the cultured bacteria; detecting the presence or absence of purine-decomposing ability and gas-producing ability; and then selecting Lactobacillus which has purine-decomposing ability but not gas-producing ability. Detection of purine-decomposing ability and gas-producing ability can be performed by known methods, and as an example, they can be performed by the methods in the Examples.
Media that are generally suitable for culturing lactic acid bacilli may be used for culturing the lactic acid bacteria of the genus Lactobacillus of the present invention, and media comprising carbon sources such as glucose, lactose, galactose, fructose, trehalose, sucrose, mannose, and cellobiose; nitrogen sources such as meat extracts, peptone, yeast extracts, casein, and whey proteins; and inorganic nutrients such as magnesium sulfate, iron sulfate, and manganese sulfate can be used. One preferable example includes Lactobacilli MRS Broth (Difco). The culture conditions are not particularly restricted, as long as the growth of intestinal lactobacilli is possible. Preferable conditions include, for example, pH5.0 to pH8.0, and temperature of 20 C to 45 C, and more preferable conditions are anaerobic, pH5.0 to pH7.0, and temperature of 30 C to 40 C.
As described later, the present inventors orally administered the lactic acid bacteria of the genus Lactobacillus of the present invention to model animals, and confirmed that these lactic acid bacteria have an effect of suppressing the increase of blood uric acid levels.
Therefore, lactic acid bacteria of the genus Lactobacillus of the present invention can be used to suppress the increase in blood uric acid levels or prevent and/or treat hyperuricemia.
Furthermore, it may be possible to manufacture foods that contain a reduced amount of purines using the purine-decomposing ability of the lactic acid bacteria of the genus Lactobacillus of the present invention.
Specific examples of "lactic acid bacteria of the genus Lactobacillus having purine-decomposing ability but not gas-producing ability" in the present invention include Lactobacillus gasseri 0LL2959 specified by Accession No.: NITE BP-224. The present inventors examined the presence or absence of purine-decomposing ability and gas-producing ability for a large number of lactic acid bacteria, and specifically found that the lactic acid bacteria of the genus Lactobacillus named Lactobacillus gasseri 0LL2959 has purine-decomposing ability but not gas-producing ability. Furthermore, they determined through in vivo experiments that Lactobacillus gasseri 0LL2959 significantly suppresses the increase in blood uric acid level. The present inventors deposited the above-mentioned bacterial strain with the Patent Microorganisms Depositary (NPMD) of the National Institute of Technology and Evaluation. Contents specifying the deposit are described below.
(A) Depositary institution: Patent Microorganisms Depositary (NPMD) of the National Institute of Technology and Evaluation (Location: 2-5-8, Kazusakamatari, Kisarazu-city, Chiba, 292-0818, Japan) (B) Original date of deposition: March 31, 2006 Date of transfer from domestic deposit to deposit under the Budapest Treaty:
November 21, 2007 (C) Accession No.:
Lactobacillus gasseri strain 0LL2959 (Accession No.: NITE BP-224) Furthermore, the present invention relates to Lactobacillus oris (lactic acid bacteria) which has purine-decomposing ability. The present invention is based on the present inventors' initial discovery of lactic acid bacteria Lactobacillus oris which have purine-decomposing ability (hereinafter, also referred to as "lactic acid bacteria Lactobacillus oris of the present invention").
Lactobacillus oris (lactic acid bacteria) of the present invention can be separated and cultured by a method similar to the above-described method for separation and culture of lactic acid bacteria of the genus Lactobacillus of the present invention.
Furthermore, lactic acid bacteria Lactobacillus oris of the present invention can also be used for suppressing the increase in blood uric acid levels, or prevention and/or treatment of hyperuricemia.
Specific examples of "Lactobacillus oris (lactic acid bacteria) with purine-decomposing ability" of the present invention include Lactobacillus oris 0LL2779 specified by Accession No.: NITE BP-223. From a large number of lactic acid bacteria, the present inventors found Lactobacillus oris 0LL2779 as a lactic acid bacterium having purine-decomposing ability, and discovered through in vivo experiments that Lactobacillus oris 0LL2779 significantly suppresses the increase in blood uric acid levels. The present inventors deposited the above-mentioned bacterial strain with the Patent Microorganisms Depositary (NPMD) of the National Institute of Technology and Evaluation. Contents specifying the deposit are described below.
(A) Depositary institution: Patent Microorganisms Depositary (NPMD) of the National Institute of Technology and Evaluation (Location: 2-5-8, Kazusalcamatari, Kisarazu-city, Chiba, 292-0818, Japan) (B) Original date of deposition: March 31, 2006 Date of transfer from domestic deposit to deposit under the Budapest Treaty:
November 21, 2007 (C) Accession No.:
Lactobacillus oris strain 0LL2779 (Accession No.: NITE BP-223) Lactic acid bacteria of the genus Lactobacillus of the present invention and lactic acid bacteria Lactobacillus oris of the present invention can be used to manufacture dietary products or pharmaceuticals for suppressing the increase in blood uric acid levels, and dietary products or pharmaceuticals for preventing and/or treating hyperuricemia.
Dietary products prepared using the lactic acid bacteria of the genus Lactobacillus of the present invention and lactic acid bacteria Lactobacillus oris of the present invention are not limited in terms of their category or type and may be functional food, specified health food, health food, nursing care food, or may be dairy products such as confectionary, lactic acid bacteria beverage, cheese, or yogurt, flavoring agents, or such. The form of the dietary product is also not limited, and may take the form of any dietary product that may be commonly distributed such as a solid, liquid, fluid diet, jelly, tablets, granules, or capsules. The above-mentioned dietary products can be manufactured through methods that are ordinary to those skilled in the art. In producing the above-mentioned dietary products, carbohydrates, proteins, lipids, dietary fibers, vitamins, biologically essential trace metals (manganese sulfate, zinc sulfate, magnesium chloride, potassium carbonate, etc.), flavors, or other compositions may be added, as long as they do not interfere with the growth of lactic acid bacteria.
The lactic acid bacteria of the genus Lactobacillus of the present invention and lactic acid bacteria Lactobacillus oris of the present invention, material containing these lactic acid bacteria and/or processed material thereof (for example, culture, concentrate, paste material, spray-dried material, freeze-dried material, vacuum-dried material, drum-dried material, fluid material, dilution material, and homogenate) can be processed into common dietary products comprising dairy products/fermented milk as described above, and used as starters for producing dairy products/fermented milk such as yogurt and cheese. When they are used as starters, other microorganisms may be admixed as long as they do not interfere with the manufacturing of dairy products or the inhabitation/proliferation of the lactic acid bacteria of the genus Lactobacillus of the present invention and lactic acid bacteria Lactobacillus oris of the present invention. For example, they may be admixed with Lactobacillus delbruekii subsp. bulgaricus, Streptococcus thermophilus, or Lactobacillus acidophilus which are major bacterial species of lactic acid bacteria in yogurt, and additionally, they may be admixed with bacterial species generally used for yogurt or cheese and made into starters. Dairy products and fermented milk can be manufactured using the above-mentioned starters by ordinary methods. For example, plain yogurt can be manufactured by admixing the above-mentioned starter with milk or dairy products that have been subjected to heating, mixing, homogenization, sterilization treatment, and cooling, followed by fermentation and cooling.
The lactic acid bacteria of the genus Lactobacillus of the present invention and lactic acid bacteria Lactobacillus oris of the present invention can be admixed with physiologically acceptable carriers, excipients, diluting agents, or such, and administered orally or parenterally as pharmaceutical compositions; however, the preferred method of administration is oral administration. Formulations for oral administration can be prepared as various well-known dosage forms, and such examples include granules, powders, tablets, pills, capsules, liquids, syrups, emulsions, suspensions, and troches. Furthermore, by preparing an enteric-coated formulation by methods well-known to those skilled in the art, the lactic acid bacteria of the genus Lactobacillus of the present invention can be transported efficiently to the intestine without being affected by gastric acid.
Pharmaceuticals and dietary products manufactured using the lactic acid bacteria of the genus Lactobacillus of the present invention and lactic acid bacteria Lactobacillus oris of the present invention can be expected to display an effect of suppressing the increase in blood uric acid levels or an effect of preventing and/or treating hyperuricemia through the actions of these bacteria in the dietary products.
Furthermore, by using the purine-decomposing ability of the lactic acid bacteria of the genus Lactobacillus of the present invention and lactic acid bacteria Lactobacillus oris of the present invention, dietary products with reduced purine levels can also be manufactured.
Methods of the present invention for manufacturing dietary products with reduced purine levels comprise the step of contacting the lactic acid bacteria of the genus Lactobacillus of the present invention and lactic acid bacteria Lactobacillus oris of the present invention with a raw material or intermediate product of the dietary product. This step efficiently reduces the amount of purine contained in the raw materials or intermediate products. The above-mentioned step is preferably carried out under conditions in which the lactic acid bacteria of the genus Lactobacillus of the present invention and lactic acid bacteria Lactobacillus oris of the present invention are viable. In addition to the above-mentioned step, the manufacturing method of the present invention may comprise common steps for manufacturing dietary products of interest such as a crushing step, admixing step, drying step, sterilization step, and packing step. Dietary products manufactured by the methods of the present invention are not limited in terms of their category or type and may be, for example, functional food, specified health food, health food, nursing care food, or common food, for example, food categorized as tasty food; however, they are particularly useful as a daily dietary product or supplementary dietary product for patients with a disease or symptom that requires limiting purine intake, or the high-risk group for the above-mentioned disease or symptoms. The methods of the present invention enable people who need to limit their purine intake or people who want to control their purine intake to consume foods normally high in purine level and enjoy their nutrients or taste.
Examples Herein below, the present invention will be specifically described with reference to the Examples, but it is not to be construed as being limited thereto. In the Examples, the bacterial strains indicated as JCM in the bacterial strain name are standard strains obtained from the Japan Collection of Microorganisms RIKEN BioResource Center, the bacterial strains indicated as ATCC in the bacterial strain name are standard strains obtained from the American Type Culture 5 Collection, and the bacterial strains indicated as MEP in the bacterial strain name are bacterial strains held by Meiji Dairies Corporation.
[Example 1] In vitro experiment method on the uric acid-reducing effect of lactic acid bacteria The following method was used to examine the presence or absence of 10 purine-decomposing ability in each type of lactic acid bacteria.
Using a Difco Lactobacilli MRS Broth (manufactured by BD) medium, each type of lactic acid bacteria (bacterial cells) was placed in a sealed container with an oxygen adsorbing agent "AnaeroPack" (manufactured by Mitsubishi Gas Co.) and anaerobically cultured overnight at a temperature of 37 C. The bacterial suspension solution obtained after culturing was subjected to centrifugal separation at a rotation frequency of 3000 rpm for 10 minutes at a temperature of 4 C to precipitate and collect (harvest) the bacterial cells.
A lx 109 CFU/mL bacterial cell suspension solution was prepared from these bacterial cells using a 0.1 M sodium phosphate buffer.
After preparing the various types of bacterial cell suspension solutions, inosine and guanosine were each added at 1.25 mM to every bacterial cell suspension solution. These bacterial cell suspension solutions were placed in a 37 C constant temperature bath, and then shake cultured at a horizontal rotation frequency of 140 rpm for 30 minutes or two hours.
The consumption level of nucleosides and the production level of bases (hypoxanthine and guanine), which are degradation products of nucleosides, in the shake cultured bacterial cell suspension solutions (reaction solutions) were measured on HPLC using 5-bromouracil as the internal standard. 200 gL of the reaction solution was added to 780 pL of mobile phase A, and 20 gL of 5-bromouracil (1.6 mg/mL) was added as the internal standard and mixed. This mixed solution was filtered with a filter (pore size 0.45 gm), and then 501.11. of the filtered solution was injected into HPLC. The specific operational conditions of the HPLC are as follows.
HPLC: Waters alliance 2690 Column: CAPCELL PAK C18 SG120, particle diameter 5 gm, column size 4.6 x 250 mm (Shiseido) Mobile phase: A: 25 mM KH2PO4 (0.1% methanol) B: 25 mM KH2PO4 (0.1% methanol)/methanol (75:25) gradient A/B (min): 100/0 (0) - 100/0 (10) - 20/80 (20) - 20/80 (25) -100/0 (26) - 100/0 (40) Detector: photodiode array (Waters 996) detection wavelength of 254 nm Flow rate: 1 mL/min Column temperature: room temperature The results are shown in Figs. 1 to 3. Each compound was quantified based on the peak area values in the HPLC chart. Furthermore, the degradation rates for Figs. 1 and 2 were calculated according to the following equation:
Degradation rate = 100 - (amount of inosine or guanosine / amount of inosine or guanosine in the blank) x 100.
The calculation method for Fig. 3 is as follows:
(amount of hypoxanthine + amount of guanine) / amount of 5-bromouracil Based on the results of Figs. 1 to 3, lactic acid bacteria assessed to have remarkable nucleoside-decomposing ability were selected.
[Example 2] In vivo experiment method on the uric acid-reducing effect of lactic acid bacteria Dietary hypertuicemia model animals were produced according to the method described in prior literature (Non-patent Document 1), and the effects of microorganisms (lactic acid bacteria) on the animals' serum uric acid levels were examined. Specifically, the above-mentioned method is a method that prepares a mixed feed containing 2.5 weight %
potassium oxonate and 1.0 weight % RNA, feeds rats with the mix, and compares the post-intake blood uric acid levels with those of the negative group and the control group.
It has been found that when the model animals in this method are given an oral administration of allopurinol which is an inhibitor of uric acid production, the blood uric acid level in the model animals is significantly suppressed ("Shokuhin kinou kenkyu News (Food Function Research News)" vol.
14, March, 9, 2005 issue, Mercian Cleantec Co. environmental inspection center, http://www.m-cleantec.com/gizyutu/news_0503.html). This indicates that the above-mentioned method is useful as a system for evaluating the effectiveness of foods against hyperuricemia.
[2-1 Materials and Experimental Procedure]
[Microorganisms]
Five strains, Lactobacillus fermentum strain MEP181504 (hereinafter, "Lactobacillus"
will be abbreviated as "L." in some cases), L. brevis strain MEP181507, L.
gasseri strain JCM8787, L. gasseri strain 0LL2959, and L. oris strain 0LL2779, which were assessed to have high nucleoside-decomposing ability in the above-mentioned in vitro experiment, were used.
Bacterial cell suspension solutions were prepared from these various lactic acid bacteria in the same manner as in the in vitro experiments. The bacterial cell suspension solutions were orally administered to rats at 1 x 109 CFU/10 mL/kg.
[Experimental animals]
Rats (Wister SPF, male, 7 weeks old) were used. Plastic cages for rats were used for rearing (habituation and testing), and a single rat was housed in each cage.
The light-dark cycle was light from 7 a.m. to 7 p.m. (12 hours).
[Preliminary rearing (taming) and group division]
Experimental animals went through a one-week preliminary rearing (habituation) after they were brought in. During habituation, the animals were allowed to freely consume AIN-93G (Oriental Yeast Co. Ltd.) as feed (food) and tap water as drinking water. After preliminary rearing, blood was collected through the tail vein of rats (seven days after arrival, 8 weeks old, day 0) in a non-fasting state in the morning. This blood was left at room temperature for 30 minutes or more, then serum was fractionated by centrifugal separation at a rotation frequency of 10,000 rpm for 10 minutes, and then the uric acid level in the serum was measured using the phosphotungstic acid method.
Groups were divided such that the serum uric acid level in each group was the same.
A total of nine groups with five rats in each group were used in the test:
negative groups (Groups 1 and 5), control groups (Groups 2 and 6), and bacterial cell-administered groups (Groups 3, 4, and 7 to 9). The names of the groups, feed, administered substance (administration dose), number of animals, and such are indicated below.
- Negative groups (Groups 1 and 5): "AIN-93G" as feed, "physiological saline"
was administered (10 mL/kg), five animals.
- Control groups (Groups 2 and 6): "A1N-93G admixed with 2.5 weight %
potassium oxonate and 1.0 weight % RNA" as feed, "physiological saline" was administered (10 mL/kg), five animals.
- Bacterial cell-administered group (Groups 3, 4, and 7 to 9): in each group, "AIN-93G admixed with 2.5 weight % potassium oxonate and 1.0 weight % RNA" as feed, five animals. The administered bacterial cells and doses for each of the groups are as follows:
for Group 3, "a suspension solution of L. fermentum strain MEP181504 (1 x 108 CFU/mL)" was administered (10 mL/kg), for Group 4, "a suspension solution of L. brevis strain MEP181507 (1 x 108 CFU/mL)" was administered (10 mL/kg), for Group 7, "a suspension solution of L. oris strain 0LL2779 (1 x 108 CFU/mL)" was administered (10 mL/kg), for Group 8, "a suspension solution of L. gasseri strain JCM8787 (1 x 108 CFU/mL)" was administered (10 mL/kg), for Group 9, "a suspension solution of L. gasseri strain 0LL2959 (1 x 108 CFU/mL)" was administered (10 mL/kg).
[Main breeding (test)]
The test period was set to be eight days from the day after group division, and each of the "AIN-93G" feed (negative groups) and "AIN-93G + potassium oxonate + RNA"
feed (control groups and bacterial cell-administered groups) were freely fed to the rats using a diet feeder. The start date of feeding the main feed was set to Day 1, and the subsequent days were counted from this date. The "AIN-93G + potassium oxonate + RNA" feed comprises 2.5 weight % potassium oxonate (100 g, ALDRICH) and 1.0 weight % RNA (500 g, MP
Biomedicals Inc.). 1 x 109 CFU/10 mL/kg of the aforementioned bacterial cell suspension was orally administered by force to the experimental animals of the bacterial cell-administered groups. To the negative groups and control groups, 10 mL/kg of physiological saline solution instead of the bacterial cell suspension was orally administered by force.
[Measurement, examination, and such]
- Observation of the general status and measurement of body weight In all cases (all groups), the general status was observed at the time of administration every day from day 1 to day 8, and the body weight was measured at a fixed time between 9 a.m.
and 10 a.m. on days 0, 1, 5, and 8.
- Measurement of feed consumption and water consumption In all cases (all groups), feed consumption and water consumption were measured at a fixed time between 9 a.m. and 10 a.m. on day 1 (set level), day 5 (residual level, set level), and day 8 (residual level).
- Blood collection and biochemical tests In all cases (all groups), blood was collected from the tail vein on day 0 (in the morning), day 2 (one hour after administration), day 5 (one hour after administration), and day 8 (before administration). The collected blood was subjected to centrifugal separation at a rotation frequency of 10,000 rpm for ten minutes to fractionate the serum, and the uric acid level in the serum was measured by the phosphotungstic acid method. As described above, the serum uric acid levels measured on day 0 were used for group division.
- Autopsy and biochemical tests In all cases (all groups), blood collection from the tail vein on day 8 was followed by oral administration of the bacterial cell suspension solution. One hour after administration, whole blood was collected from the abdominal aorta under nembutal (pentobarbital 40 mg/kg) anesthesia and the animal died. The collected blood was centrifuged at a rotation frequency of 3000 rpm for 15 minutes to fractionate the serum, and then creatinine, uric acid, and urea nitrogen in the serum were measured.
- Measurement of organ weight The liver was excised from the rat, and its wet weight was measured.
[Statistical processing]
The results are indicated as the mean standard deviation, and the control groups were compared with each of the bacterial cell-administered groups. Variance ratios of the numerically converted test values were tested by the F test, Student's t-test was used in the case of equal variance, and Aspin-Welch t-test was used in the case of unequal variance. The statistical analysis of Excel Statistics 2004 was used for statistical processing, and the lowest level of significance was set to 5% on both sides.
[2-2 Results]
The results of the general status are shown in Table 1 (L. fermentum and L.
brevis) and Table 2 (L. oris and L. gasseri), and the changes in serum uric acid levels are shown in Figs. 4 and 5.
As shown in Fig. 5, significant difference in the reduction of serum uric acid level as a result of administration of each type of lactic acid bacteria was observed in the L. oris 0LL2779-administered group and the L. gasseri 0LL2959-administered group. In terms of general status, there were no problems with the kidney function (creatinine values, serum urea nitrogen, and kidney weight), or body weight, feed consumption, and water consumption in any of the groups. Furthermore, no significant difference in the general status observed was found among the various types of lactic acid bacteria. The scientific characteristics of L. oris 0LL2779 and L. gasseri 0LL2959 are shown in Table 3.
=
cr AMOUNT OF BODY WEIGHT INCREASE
28.6 2.3 23.0 -1- 2.9 20.0 -1- 3.5 20.0 3.7 DURING THE TESTING PERIOD (g) FEED CONSUMPTION
DURING THE TESTING PERIOD (g) 106.9 7.7 88.2 -1- 3.9 82.7 - 4.2 85.1 6.3 WATER COMSUMPTION 96.7 -I- 15.1 192.2 I- 11.9 183.3 -1-12.7 190.8 16.7 DURING THE TESTING PERIOD (g) SERUM CREATININE LEVEL 0.7 0.1 0.8 0.1 0.8 0.1 0.8 0.0 (DAY 8) (mg/dL) AMOUNT OF SERUM UREA NITROGEN 15.5 1.5 15.2 -I- 2.4 16.3 2.0 14.8 1.7 (DAY 8) (mg/dL) ABSOLUTE KIDNEY WEIGHT
(DAY 8) (g) 1.5 0.1 1.6 0.0 1.6 0.1 1.6 -I- 0.1 o CO
o CO
o 1-`
o o CO
cr AMOUNT OF BODY WEIGHT INCREASE
DURING THE TESTING PERIOD (g) 29.2 2.8 18.4 7.3 19.2 1.4 18.6 4.0 21.3 4.5 FEED CONSUMPTION
DURING THE TESTING PERIOD (g) 102.8 7.4 87.6 4.7 87.8 4.4 94.4 12.3 87.9 6.7 WATER COMSUMPT I ON
DURING THE TESTING PERIOD (g) 108-0 13-0 17" 15-3 173.0 134 183.6 8.1 168.2 - 13.1 SERUM GREAT I N I NE LEVEL
(DAY 8) (mg/dL) 0.7 - 0.0 0.8 0.1 0.7 0.0 0.7 0.1 0.7 0.0 SERUM UREA NITROGEN LEVEL
(DAY 8) (mg/dL) 14.5 1.1 14.5 2.0 13.5 0.7
15.1 2.4 13.1 -I- 1.4 ABSOLUTE KIDNEY WE I GHT
(DAY 8) (g) 1.5 0.1 1.6 0.0 1.6 0.1 1.6 0.1 1.6 0.1 o N.) CO
o CO
o o o CO
Table 3 Lactobac i I I us Lactobac i I I us gasseri 0LL2959 or i s 0LL2779 (L gasseri 0LL2959) (L or i s 0LL2779) (NITE BP-224) INITE BP-223) culture temperature: 37 C cu I ture temperature: 31 C
CULTURE CONDITIONS oxygen raNgbe ?gilNatTe'rannalg1;e COLONY CHARACTERISTICS
ON THE MEDIUM round, pale yellow, round, pale yellow, (Lactobacilli MRS Agar, D I FCO) smooth type, flat smooth type, flat BACTERIAL FORM bacillus bacillus GRAM STAINING positive positive FORM OF LACTIC FERMENTATION 4 ZNIIgn homolactic fermentation AEROBIC GROWTH
15 C¨ 15t ¨
GROWTH TEMPERATURE
45 C + 45 C +
ARAB I NOSE
XYLOSE
RAMNOSE
RIBOSE
GLUCOSE
MANNOSE
FRUCTOSE
OE
GALACTOSE
1.1.1 SUCROSE
CELLOB I OSE
LACTOSE
TREHALOSE
MEL I B I OSE
RAFF I NOSE
MEL I CI TOSE
MANN I TOL
SORB! TOL
GAS PRODUCTION
[Example 3] Production of fermented milk (Example 1 on the production of fermented milk) Plain yogurt was prepared using L. gasseri 0LL2959 (NITE BP-224), L.
bulgaricus JCM 1002T, and S. thermophilus ATCC19258. First, bulk starters of L. gasseri 0LL2959 (NITE
BP-224), L. bulgaricus JCM1002T, and S. thermophilus ATCC19258 were prepared using a 10%
powdered skim milk medium. Next a yogurt mix (non-fat milk solid (SNF): 9.5%, fat (FAT):
3.0%) was subjected to heat treatment at 95 C for five minutes. After heat treatment, this yogurt mix was inoculated with 1% of L. bulgaricus JCM1002T starter, 1% of S.
thermophilus ATCC19258 starter, and 5% of L. gasseri 0LL2959 (NITE BP-224) starter, and then fermented at 43 C for four hours to obtain plain yogurt. This plain yogurt was cooled in the refrigerator (5 C), and then its flavor and physical properties were checked. Both the flavor and physical properties were satisfactory.
(Example 2 on the production of fermented milk) Plain yogurt was prepared using L. oris 0LL2779 (NITE BP-223), L. bulgaricus JCM1002T, and S. thermophilus ATCC19258. First, bulk starters of L. oris 0LL2779 (NITE
BP-223), L. bulgaricus JCM1002T, and S. thermophilus ATCC19258 were prepared using a 10%
powdered skim milk medium. Next a yogurt mix (non-fat milk solid (SNF): 9.5%, fat (FAT):
3.0%) was subjected to heat treatment at 95 C for five minutes. After heat treatment, this yogurt mix was inoculated with 1% of L. bulgaricus JCM1002T starter, 1% of S.
thermophilus ATCC19258 starter, and 5% of L. oris 0LL2779 (NITE BP-223) starter, and then fermented at 43 C for four hours to obtain plain yogurt. This plain yogurt was cooled in the refrigerator (5 C), and then its flavor and physical properties were checked. Both the flavor and physical properties were satisfactory, and this confirmed that L. oris 0LL2779 can be used favorably for manufacturing food.
Industrial Applicability The present invention provides lactic acid bacteria capable of reducing the blood uric acid level. Since oral intake of the lactic acid bacteria of the present invention can lower blood uric acid levels, the lactic acid bacteria of the present invention can be used as foods or pharmaceuticals for preventing and/or treating gout or hyperuricemia. In particular, it has been confirmed that the problem of gas production does not happen when the lactic acid bacteria of the present invention are used in food manufacturing, and thus they are likely to be suitable for practical applications. Furthermore, it may become possible to manufacture processed foods with reduced purine levels by using the lactic acid bacteria of the present invention. This way, the lactic acid bacteria of the present invention are likely to be very highly useful for the food and pharmaceutical industry.
(DAY 8) (g) 1.5 0.1 1.6 0.0 1.6 0.1 1.6 0.1 1.6 0.1 o N.) CO
o CO
o o o CO
Table 3 Lactobac i I I us Lactobac i I I us gasseri 0LL2959 or i s 0LL2779 (L gasseri 0LL2959) (L or i s 0LL2779) (NITE BP-224) INITE BP-223) culture temperature: 37 C cu I ture temperature: 31 C
CULTURE CONDITIONS oxygen raNgbe ?gilNatTe'rannalg1;e COLONY CHARACTERISTICS
ON THE MEDIUM round, pale yellow, round, pale yellow, (Lactobacilli MRS Agar, D I FCO) smooth type, flat smooth type, flat BACTERIAL FORM bacillus bacillus GRAM STAINING positive positive FORM OF LACTIC FERMENTATION 4 ZNIIgn homolactic fermentation AEROBIC GROWTH
15 C¨ 15t ¨
GROWTH TEMPERATURE
45 C + 45 C +
ARAB I NOSE
XYLOSE
RAMNOSE
RIBOSE
GLUCOSE
MANNOSE
FRUCTOSE
OE
GALACTOSE
1.1.1 SUCROSE
CELLOB I OSE
LACTOSE
TREHALOSE
MEL I B I OSE
RAFF I NOSE
MEL I CI TOSE
MANN I TOL
SORB! TOL
GAS PRODUCTION
[Example 3] Production of fermented milk (Example 1 on the production of fermented milk) Plain yogurt was prepared using L. gasseri 0LL2959 (NITE BP-224), L.
bulgaricus JCM 1002T, and S. thermophilus ATCC19258. First, bulk starters of L. gasseri 0LL2959 (NITE
BP-224), L. bulgaricus JCM1002T, and S. thermophilus ATCC19258 were prepared using a 10%
powdered skim milk medium. Next a yogurt mix (non-fat milk solid (SNF): 9.5%, fat (FAT):
3.0%) was subjected to heat treatment at 95 C for five minutes. After heat treatment, this yogurt mix was inoculated with 1% of L. bulgaricus JCM1002T starter, 1% of S.
thermophilus ATCC19258 starter, and 5% of L. gasseri 0LL2959 (NITE BP-224) starter, and then fermented at 43 C for four hours to obtain plain yogurt. This plain yogurt was cooled in the refrigerator (5 C), and then its flavor and physical properties were checked. Both the flavor and physical properties were satisfactory.
(Example 2 on the production of fermented milk) Plain yogurt was prepared using L. oris 0LL2779 (NITE BP-223), L. bulgaricus JCM1002T, and S. thermophilus ATCC19258. First, bulk starters of L. oris 0LL2779 (NITE
BP-223), L. bulgaricus JCM1002T, and S. thermophilus ATCC19258 were prepared using a 10%
powdered skim milk medium. Next a yogurt mix (non-fat milk solid (SNF): 9.5%, fat (FAT):
3.0%) was subjected to heat treatment at 95 C for five minutes. After heat treatment, this yogurt mix was inoculated with 1% of L. bulgaricus JCM1002T starter, 1% of S.
thermophilus ATCC19258 starter, and 5% of L. oris 0LL2779 (NITE BP-223) starter, and then fermented at 43 C for four hours to obtain plain yogurt. This plain yogurt was cooled in the refrigerator (5 C), and then its flavor and physical properties were checked. Both the flavor and physical properties were satisfactory, and this confirmed that L. oris 0LL2779 can be used favorably for manufacturing food.
Industrial Applicability The present invention provides lactic acid bacteria capable of reducing the blood uric acid level. Since oral intake of the lactic acid bacteria of the present invention can lower blood uric acid levels, the lactic acid bacteria of the present invention can be used as foods or pharmaceuticals for preventing and/or treating gout or hyperuricemia. In particular, it has been confirmed that the problem of gas production does not happen when the lactic acid bacteria of the present invention are used in food manufacturing, and thus they are likely to be suitable for practical applications. Furthermore, it may become possible to manufacture processed foods with reduced purine levels by using the lactic acid bacteria of the present invention. This way, the lactic acid bacteria of the present invention are likely to be very highly useful for the food and pharmaceutical industry.
Claims (13)
1. A lactic acid bacterium Lactobacillus oris OLL2779 (Accession No.: NITE
BP-223).
BP-223).
2. The lactic acid bacterium of claim 1 or a substance containing said lactic acid bacterium, or combination thereof, for use in treating or preventing, in a subject, one or more diseases or symptoms selected from the group consisting of hyperuricemia, gout, renal dysfunction, urinary stone, and arteriosclerosis.
3. The lactic acid bacterium for use of claim 2, wherein the disease or symptom is hyperuricemia.
4. A dietary product comprising one or both of the lactic acid bacterium of claim 1 and a substance containing said lactic acid bacterium.
5. The dietary product of claim 4, for use in preventing or treating, in a subject, one or more diseases or symptoms selected from the group consisting of hyperuricemia, gout, renal dysfunction, urinary stone, and arteriosclerosis.
6. The dietary product for use of claim 5, wherein the disease or symptom is hyperuricemia.
7. A pharmaceutical composition comprising one or both of the lactic acid bacterium of claim 1 and a substance containing said lactic acid bacterium, together with a pharmaceutically acceptable carrier.
8. The pharmaceutical composition of claim 7, for use in preventing or treating, in a subject, one or more diseases or symptoms selected from the group consisting of hyperuricemia, gout, renal dysfunction, urinary stone, and arteriosclerosis.
9. The pharmaceutical composition for use of claim 8, wherein the disease or symptom is hyperuricemia.
10. Use of the lactic acid bacterium of claim 1 or a substance containing said lactic acid bacterium, or combination thereof, in the manufacture of a dietary product or a pharmaceutical composition for preventing or treating, in a subject, one or more diseases or symptoms selected from the group consisting of hyperuricemia, gout, renal dysfunction, urinary stone, and arteriosclerosis.
11. Use of the lactic acid bacterium of claim 1 or a substance containing said lactic acid bacterium, or combination thereof, or the dietary product of claim 4 or the pharmaceutical composition of claim 7, for preventing or treating, in a subject, one or more diseases or symptoms selected from the group consisting of hyperuricemia, gout, renal dysfunction, urinary stone, and arteriosclerosis.
12. The use of claim 10 or 11, wherein the disease or symptom is hyperuricemia.
13. A method for producing a dietary product with reduced purine level, wherein the method comprises the step of contacting a raw material or intermediate product of the dietary product with one or both of the lactic acid bacterium of claim 1 and a substance containing said lactic acid bacterium.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2851018A CA2851018C (en) | 2007-11-29 | 2007-11-29 | Lactic acid bacteria having action of lowering blood uric acid level |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2851018A CA2851018C (en) | 2007-11-29 | 2007-11-29 | Lactic acid bacteria having action of lowering blood uric acid level |
CA2718157A CA2718157C (en) | 2007-11-29 | 2007-11-29 | Lactobacillus gasseri capable of lowering blood uric acid level |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2718157A Division CA2718157C (en) | 2007-11-29 | 2007-11-29 | Lactobacillus gasseri capable of lowering blood uric acid level |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2851018A1 CA2851018A1 (en) | 2009-06-04 |
CA2851018C true CA2851018C (en) | 2017-10-03 |
Family
ID=50830982
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2851018A Active CA2851018C (en) | 2007-11-29 | 2007-11-29 | Lactic acid bacteria having action of lowering blood uric acid level |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2851018C (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3165599A4 (en) * | 2014-05-29 | 2017-12-27 | Nitto Pharmaceutical Industries, Ltd. | Novel lactic acid bacterium and composition including said lactic acid bacterium |
CN112574917B (en) * | 2020-12-16 | 2022-08-09 | 无锡特殊食品与营养健康研究院有限公司 | Lactobacillus rhamnosus CCFM1131 for relieving hyperuricemia |
CN116024130B (en) * | 2022-12-13 | 2023-11-24 | 广西爱生生命科技有限公司 | Lactobacillus fermentum A21215 for reducing blood uric acid and application thereof |
-
2007
- 2007-11-29 CA CA2851018A patent/CA2851018C/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2851018A1 (en) | 2009-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2718157C (en) | Lactobacillus gasseri capable of lowering blood uric acid level | |
EP2221360B1 (en) | Lactic acid bacterium having effect of lowering blood uric acid level | |
JP5237581B2 (en) | Lactic acid bacteria with action to reduce blood uric acid level | |
US9283252B2 (en) | Lactic acid bacterium having high oxalic acid decomposition ability | |
CN102747004B (en) | Lactic acid bacteria with effect of uric acid level reducing in blood | |
WO2016002757A1 (en) | Lactic acid bacterium for suppressing purine absorption and use for same | |
JP5597237B2 (en) | Lactic acid bacteria with action to reduce blood uric acid level | |
CA2851018C (en) | Lactic acid bacteria having action of lowering blood uric acid level | |
JPWO2016080371A1 (en) | Lactic acid bacteria having purine uptake ability and uses thereof | |
JP2003252770A (en) | Agent for prevention, improvement and treatment of diabetic complication | |
JP6654824B2 (en) | Blood uric acid level reducer | |
TWI479020B (en) | Lactic acid bacteria having a function of lowering uric acid in blood | |
TWI405849B (en) | Lactic acid bacteria having a function of lowering uric acid in blood |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20140508 |